Skip to main content

Table 4 Odds of bladder cancer associated with As3MT SNPs and arsenic from drinking water (in quartiles†)

From: Genetic variation in Glutathione S-Transferase Omega-1, Arsenic Methyltransferase and Methylene-tetrahydrofolate Reductase, arsenic exposure and bladder cancer: a case–control study

SNP

Major allele homozygote

Minor allele carrier

 
 

Cases n (%)

Controls n (%)

Age and smoking adjusted OR (95% CI)

Cases n (%)

Controls n (%)

Age and smoking adjusted OR (95% CI)

p-interaction

As3MT

       

rs1046778

      

Q1

30 (26.8)

33 (24.6)

1.00

30 (29.1)

35 (25.4)

1.00

Q2

29 (25.9)

30 (22.4)

0.93 (0.44 - 1.97)

23 (22.3)

39 (28.3)

0.71 (0.34 – 1.46)

Q3

25 (22.3)

34 (25.4)

0.81 (0.38 - 1.71)

23 (22.3)

34 (24.6)

0.77 (0.37 - 1.61)

Q4

28 (25.0)

37 (27.6)

0.74 (0.36 - 1.56)

27 (26.2)

30 (21.7)

1.14 (0.55 - 2.36)

Continuous‡

112 (45.5)

134 (54.5)

1.00 (0.95 – 1.05)

103 (42.7)

138 (57.3)

1.03 (0.99 – 1.08)

0.33

rs3740400

       

Q1

23 (28.8)

19 (16.8)

1.00

38 (27.9)

49 (31.0)

1.00

Q2

24 (30.0)

28 (24.8)

0.60 (0.25 - 1.43)

28 (20.6)

41 (25.9)

0.87 (0.45 - 1.69)

Q3

18 (22.5)

27 (23.9)

0.55 (0.22 - 1.36)

30 (22.1)

40 (25.3)

0.94 (0.49 - 1.82)

Q4

15 (18.8)

39 (34.5)

0.24 (0.10 - 0.60)

40 (29.4)

28 (17.7)

2.08 (1.06 – 4.07)

Continuous

80 (41.5)

113 (58.6)

0.96 (0.91 – 1.02)

136 (46.3)

158 (53.7)

1.08 (1.02 – 1.14)

0.006

rs11191439

       

Q1

48 (27.9)

46 (20.7)

1.00

13 (30.2)

21 (43.8)

1.00

Q2

44 (25.6)

57 (25.7)

0.71 (0.40 - 1.28)

7 (16.3)

11 (22.9)

0.96 (0.27 – 3.37)

Q3

39 (22.7)

58 (26.1)

0.62 (0.34 - 1.12)

9 (20.9)

10 (20.8)

1.68 (0.49 – 5.75)

Q4

41 (23.8)

61 (27.5)

0.61 (0.34 - 1.09)

14 (32.6)

6 (12.5)

6.88 (1.72 – 27.6)

Continuous

172 (43.7)

222 (56.4)

1.00 (0.97 - 1.04)

43 (47.3)

48 (52.8)

1.17 (1.04 – 1.32)

0.02

rs11191438

       

Q1

19 (26.8)

19 (18.4)

1.00

42 (28.8)

49 (29.0)

1.00

Q2

22 (31.0)

23 (22.3)

0.72 (0.28 - 1.84)

30 (20.5)

46 (27.2)

0.79 (0.42 - 1.49)

Q3

16 (22.5)

29 (28.2)

0.49 (0.19 - 1.26)

33 (22.6)

39 (23.1)

0.98 (0.52 - 1.86)

Q4

14 (19.7)

32 (31.1)

0.28 (0.10 - 0.74)

41 (28.1)

35 (20.7)

1.60 (0.85 – 3.03)

Continuous

71 (40.8)

103 (59.2)

0.96 (0.90 – 1.03)

146 (46.4)

169 (53.7)

1.04 (1.00 – 1.09)

0.04

rs7085104

       

Q1

25 (29.1)

20 (16.8)

1.00

35 (26.5)

48 (31.6)

1.00

Q2

26 (30.2)

30 (25.2)

0.59 (0.26 - 1.36)

28 (21.2)

39 (25.7)

0.99 (0.50 - 1.95)

Q3

20 (23.3)

28 (23.5)

0.57 (0.24 - 1.37)

29 (22.0)

39 (25.7)

0.99 (0.50 - 1.93)

Q4

15 (17.4)

41 (34.5)

0.23 (0.09 - 0.55)

40 (30.3)

26 (17.1)

2.46 (1.23 – 4.92)

Continuous

86 (42.0)

119 (58.1)

0.96 (0.91-1.01)

132 (46.5)

152 (53.5)

1.09 (1.03 – 1.16)

0.002

  1. † Quartile distribution of average arsenic exposure for among all genotyped participants.
  2. Q1 = 1st quartile (< 0.55 μg/L).
  3. Q2 = 2nd quartile (0.55-1.45 μg/L).
  4. Q3 = 3rd quartile (1.45-3.72 μg/L).
  5. Q4 = 4th quartile (>3.72 μg/L).
  6. ‡ Odds Ratio per one unit increase in the continuous measure of lifetime arsenic exposure by genotype adjusted for age and smoking history (ever/never).
Back to article page

Environmental Health

ISSN: 1476-069X